Page last updated: 2024-12-06

fiacitabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Fiacitabine, also known as FMAU (2'-fluoro-5-methyl-beta-arabinofuranosyl uracil), is a nucleoside analog that has shown promising activity against a variety of viral infections, particularly herpes simplex virus (HSV) and cytomegalovirus (CMV). Its mechanism of action involves inhibiting viral DNA polymerase, thereby preventing viral replication. Fiacitabine is synthesized through a multi-step process involving the modification of arabinose sugar and the attachment of uracil base. It has been studied extensively in preclinical models and clinical trials, demonstrating potent antiviral activity and favorable pharmacokinetic properties. Fiacitabine is being explored as a potential therapeutic agent for the treatment of herpes infections, particularly in cases of drug-resistant strains. Its importance lies in the potential to provide a safe and effective treatment option for patients with viral infections that are unresponsive to conventional antiviral drugs.'

fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID50312
CHEMBL ID272557
SCHEMBL ID138934
MeSH IDM0085904

Synonyms (51)

Synonym
fluorviodoaracytidine
fiacitabine [usan:inn]
2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine
drg-0077
cytosine, 1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo-
fluoroiodoaracytidine
2(1h)-pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo-
fiacitabinum [inn-latin]
1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodocytosine
brn 0679252
fiacitabina [inn-spanish]
HY-50735
D04180
fiacitabine (usan/inn)
nsc-382097
1-(2'-deoxy-2'-fluoro-.beta.-d-arabinofuranosyl)-5-iodocytosine
4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-iodo-pyrimidin-2-one
2'-fluoro-5-iodo-aracytosine
fiac
fiacitabine
fi-ara-c
69123-90-6
CHEMBL272557
4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one
fiacitabina
nsc 382097
4058h365zb ,
fiacitabinum
unii-4058h365zb
CS-0323
SCHEMBL138934
cas-69123-90-6
dtxcid6031596
dtxsid8057807 ,
tox21_113954
NCGC00262963-01
fiacitabine [inn]
fiacitabine [mart.]
2(1h)-pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-.beta.-d-arabinofuranosyl)-5-iodo-
1-(2-deoxy-2-fluoro-.beta.-d-arabinofuranosyl)-5-iodocytosine
fiacitabine [usan]
AKOS027327934
mfcd00868897
DB12901
F13670
4-amino-1-((2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-iodopyrimidin-2(1h)-one
Q27258286
cis-(-)-4-(methoxycarbonyl)-3-methyl-1-phenethyl-4-(n-phenylpropionylamino)piperidiniumhydrogenoxalate
MS-25968
NCGC00262963-03
A900506

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg."( Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines.
Hsiung, GD; Mayo, DR, 1984
)
0.27
" The dosage levels explored were 60, 120, 240, 400, and 600 mg/sq m/day."( Phase I evaluation of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection.
Armstrong, D; Fox, JJ; Leyland-Jones, B; Lopez, C; Philips, FS; Schneider, R; Tan, CT; Watanabe, KA; Young, CW, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID1259243
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.34910.001022.650876.6163AID1224838
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinaseVaccinia virus WRKm135.00004.30004.30004.3000AID324741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID324743Activity of human thymidine kinase 1 assessed as ATP utilization by luciferase-based assay2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID3013The growth inhibition activity for the compound was evaluated in 2.2.15 cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID3004Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID3014Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents.
AID324742Ratio of Vmax to Km for Vaccinia virus WR thymidine kinase2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID84943Effective concentration required to inhibit replication of strain G of HSV-2 by 90%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID86034Effective concentration required to inhibit replication of strain F of HSV-1 by 90%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID324741Activity of Vaccinia virus WR thymidine kinase assessed as ATP utilization by luciferase-based assay2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID216191Compound was evaluated for cytotoxicity in rapidly dividing Vero cells1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID84941Effective concentration required to inhibit replication of strain G of HSV-2 by 50%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID324744Ratio of Vmax to Km for human thymidine kinase 12007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
AID86032Effective concentration required to inhibit replication of strain F of HSV-1 by 50%1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (67.19)18.7374
1990's8 (12.50)18.2507
2000's1 (1.56)29.6817
2010's5 (7.81)24.3611
2020's7 (10.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.49%)5.53%
Reviews6 (8.96%)6.00%
Case Studies2 (2.99%)4.05%
Observational0 (0.00%)0.25%
Other58 (86.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Oral FIAC in AIDS Patients With Cytomegalovirus Infection: A Dose Ranging Study [NCT00000981]Phase 278 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]